QLA E	4C,
O	Cusamer No. 28880
	H Am

Confirmation No. 3925

JFW

Customer N	10, 28880			Conf	irmation No. 3923	
Donder t	the Paperwork Reduction Act of 1995	. no person:		nt and Tra	PTO/SB/21 (03-C Approved for use through 04/30/2003. OMB 0551-00 ademark Office; U.S. DEPARTMENT OF COMMER(promation unless it displays a valid OMB control numb	
(3)			Application Number		5,561	
EME	TRANSMITTAL		Filing Date	12/12	2/2003	
	FORM		First Named Inventor	David	d J. Dooley	
(to be us	ed for all correspondence after initial	filing)	Art Unit	1614		
			Examiner Name	Not y	et assigned	
Total Num	nber of Pages in This Submission		Attorney Docket Number		PC25627A	
		ENCI	OSURES (Check all that	t apply))	
Ame Exte Exp Info Cert Doc Res	Transmittal Form Fee Attached endment/Reply After Final Affidavits/declaration(s) ension of Time Request ress Abandonment Request rmation Disclosure Statement tified Copy of Priority eument(s) ponse to Missing Parts/ emplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Remar	RIZATION TO CHARGE T	HE FE	After Allowance Communication to a Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Statement as Provided by 37 CFR 1.97(b) Return Post Card Certificate of Mailing under 37 CFR 1.8 EE AND ANY ADDITIONAL FEES AS AYMENT TO DEPOSIT ACCOUNT	
•						
	SIGNA	TURE C	F APPLICANT, ATTORNI	EY, O	R AGENT	
Firm or Individual Signature	Mehdi Ganjeizadeh	ade				
Date	Date Tune 8,2004					
	C	ERTIFIC	ATE OF TRANSMISSION	I/MAIL	.ING	
I hereby certif	y that this correspondence is being fa	csimile tran		ith the U	nited States Postal Service with sufficient postage as	
Typed or p	rinted					
Signature					Date	
This salls all	of information is now in the CO. CO.					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No.

703-872-9306

PC25627A

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT:

David J. Dooley, et al

EXAMINER:

Unknown

SERIAL NO.:

10/735,561

ART UNIT:

1614

FILED:

December 12, 2003

PAPER NO.:

FOR:

Gabapentin Analogues for Fibromyalgia and Other Disorders

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dated: June 8, 2004

Respectfully submitted,

Mehdi Ganjezadeh Registration No. 47,585 Warner-Lambert Company 2800 Plymouth Road

Ann Arbor, MI 48105 Tel. (734) 622-3831 Fax (734) 622-2928 STATE TO THE

PTO/SB92 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

P.O. Box 1450

Assistant Commissioner for Patents Washingtonx DXX 2023/IXX

Alexandria, VA 22313-1450

on_ June 8. 2004	
Date	
Juja	Signature
	Inja Cho
Typed or printed na	me of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Complete if Known

 Application Number
 10/735,561

 Filing Date
 12/12/2003

 First Named Inventor
 David J. Dooley

 Art Unit
 1614

 Examiner Name
 Unknown

 Attomey Docket Number
 PC25627A

			U. S. PATENT	DOCUMENTS	-
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 4,024,175	05-17-1977	G. Satzinger, et al.	
		US- 4,087,544	05-02-1978	G. Satzinger, et al.	
		^{US-} 6,306,910	10-23-2001	L. Magnus, et al.	
		US-			
	<u> </u>	US-	-		
		US-			
		US-			
		US-			
•		US-			
		US-			
		US-			

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	r Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	- pp. sam of once becamen	Or Relevant Figures Appear	1
	EP	0641330 B1	10-17-2001	R. B. Silverman, et al.		Г
	wo	98/17627 A1	04-30-1998	J. S. Bryans, et al.		Γ
	wo	99/21824 A1	05-06-1999	J. S. Bryans, et al.		Г
	wo	00/76958 A2	12-21-2000	T. R. Belliotti, et al.		
	wo	01/28978 A1	04-26-2001	J. S. Bryans, et al.		
	wo	01/42190 A1	06-14-2001	J. S. Bryans, et al.		

	_	
Examiner	Date	
	Date	ſ
Signature	Considered	
-	00113100100	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

US-

(Use as many sheets as necessary)

Application Number 10/735,561 Filing Date 12/12/2003 First Named Inventor David J. Dooley Art Unit 1614 **Examiner Name** Unknown

PC25627A

Sheet U. S. PATENT DOCUMENTS Cite Pages, Columns, Lines, Where Publication Date Name of Patentee or Examiner **Document Number** Relevant Passages or Relevant No. MM-DD-YYYY Applicant of Cited Document Initials* Figures Appear Number-Kind Code² (F known) US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication - Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁴
		WO 01/90052 A1	11-29-2001	J. S. Bryans, et al.		
		WO 02/00209 A2	1-3-2002	J. S. Bryans, et al.		
						L
	ļ					
	ľ					

Examiner	Date	
Signature	Considered	
-		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

i i		
e type a plus sign (+) inside this box 🛶	+	ĺ

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ter the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	ute for form 1449B/F	РΤΟ			plete if Known
				Application Number	10/735,561
INFORMATION DISCLOSURE				Filing Date	December 12, 2003
STATEMENT BY APPLICANT		First Named Inventor	David J. Dooley		
J . / .			/ 11 1 EIO/ 1111	Group Art Unit	1614
	(use as man)	y sheets	s as necessary)	Examiner Name	Unknown
Sheet	3	of	3	Attorney Docket Number	PC25627A

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
		M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder:more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; Vol.9, No. 10	
		A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290	
		R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199	
		D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofacial pain syndrome" Current opinions in Rheumatology 2001;13:117-127	
		E. K. GUYMER, et al., "An approach to managing fibromyalgia" Medicine Today 2002:58-59; Vol. 3, No. 12	
		L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8	
		L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and eeg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2	
		M. B. YUNUS, "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217	
			_

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

